MedTrace Logo

A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

NCT06454175 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-01-06

No results posted yet for this study

Summary

To evaluate the safety and tolerability of 15-valent HPV vaccine in 9-45year-old participants.

Conditions

  • HPV Infection
  • HPV-Related Carcinoma
  • Genital Wart
  • HPV-Related Intraepithelial Neoplasia

Interventions

BIOLOGICAL

Placebo

immunization schedule：Month 0，Month 2，Month 6

BIOLOGICAL

15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)

immunization schedule：Month 0，Month 2，Month 6

Sponsors & Collaborators

  • Shanghai Bovax Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • LIRONG HUANG, Master · Guangxi Center for Disease Prevention and Crontrol

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-03
Primary Completion
2025-02-05
Completion
2025-07-05

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06454175 on ClinicalTrials.gov